Christopher Boyce on Muck Rack

Christopher Boyce

Edinburgh
As seen in: AIChE Journal, Business Insider, Nature, Fast Company, The Conversation, ACS Publications, Flipboard, Wales Online, Yahoo Sports Canada, Rappler and
Happiness & wellbeing wizard who loves to journey deep. At my best with my feet on the ground & fresh air is on my face. Sure its the same for you too...
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Christopher

Contact Christopher, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Discovery of MK-5661, a Once-Daily Oral Na V 1.8 Inhibitor for the Treatment of Pain Click to copy article link Article link copied!

|
By Michael Breslin, Christopher Boyce, Christopher J. Bungard
| ACS Publications
Cite Jump to ExpandCollapse LetterApril 24, 2026 Discovery of MK-5661, a Once-Daily Oral NaV1.8 Inhibitor for the Treatment of Pain Click to copy article linkArticle link copied! Christopher J. Bungard* Christopher J. Bungard Discovery Chemistry, Merck & Co., Inc., West Point, Pennsylvania 19486, United States *[email protected] Michael J. Breslin Michael J. Breslin Discovery Chemistry, Merck & Co., Inc., West Point, Pennsylvania 19486, United States Christopher W. Boyce Christopher W.
Open in Who Shared Issue with article?

Discovery and development of a new oxazolidinone with reduced toxicity for the treatment of tuberculosis - Nature Medicine Original

|
By Brendan Crowley , Helena I. Boshoff, Christopher Boyce, Sangmi Oh, Firat Kaya, Véronique Dartois, Aidan Boving, Gregory T. Roberston
| Nature
Abstract Linezolid, an oxazolidinone, is a cornerstone of treatment regimens for highly drug-resistant tuberculosis but cannot be used in drug-susceptible disease because of toxicity. This toxicity results from inhibition of mammalian mitochondrial protein synthesis. Here we show the development of a new oxazolidinone, MK-7762, with antitubercular activity that is better than linezolid and limited mitochondrial protein synthesis inhibition.
Open in Who Shared View Duplicates (2) Issue with article?

MK-7602: a potent multi-stage dual-targeting antimalarial

|
By Paola Favuzza, Josephine Palandri, Wendy Bailey, Christopher Boyce
| EBioMedicine
Keywords Malaria Antimalarial drug Plasmepsin Aspartic proteases Falciparum Vivax Evidence before this study The global burden of malaria remains substantial, with increasing parasite resistance to current antimalarial drugs posing a threat to malaria control efforts. Artemisinin-based combination therapies (ACTs) have been the cornerstone of malaria treatment, but resistance to both artemisinin and partner drugs has emerged in several regions.
Open in Who Shared Issue with article?
See all 126 licensed articles (177 Total)

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Get in touch with Christopher

Contact Christopher, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified